Twelve mega-deals captured nearly 60% of all capital deployed as AI becomes table stakes — not a differentiator — for every company that wants a shot at serious funding.
---
Digital health startups raised $4 billion in venture capital funding during the first quarter of 2026, according to Rock Health's quarterly tracking report published April 6 — a billion dollars more than the same period last year, and the strongest first quarter the sector has recorded since the pandemic funding peak of 2021 and 2022.
The number is striking. What is more striking is how it was assembled. Just 12 companies absorbed 59% of all capital deployed in Q1, each landing a financing round of $100 million or more. The concentration of money at the top of the market has reached levels not seen since Q1 2022, when pandemic-era enthusiasm briefly turned digital health into a venture free-for-all. This time, the dynamic is different: investors are being deliberate, not exuberant, and the companies clearing the bar are doing so on the back of real revenue and proven workflow integration.
The Mega-Deal Landscape
The quarter's single largest transaction came from WHOOP, the wearable fitness and recovery company, which raised a $575 million Series G at a $10.1 billion valuation — nearly triple its last reported valuation — on $1.1 billion in annual recurring revenue, with Bloomberg reporting the company is eyeing an IPO. Close behind was Verily, Alphabet's precision health spin-out, which banked $300 million to accelerate its AI roadmap as it transitions to independence. OpenEvidence, an AI medical search engine now used daily by more than 40% of U.S. physicians, closed a $250 million Series D — its third funding round in under a year — after crossing $100 million in revenue. Talkiatry, which describes itself as the nation's largest private employer of psychiatrists, raised $210 million reporting 1,745% revenue growth between 2021 and 2024.
The rest of the dozen included employer-facing GLP-1 telehealth platform eMed ($200 million Series A, $2 billion-plus valuation), mental health provider platform Grow Therapy ($150 million Series D, approximately $1 billion in revenue), value-based care enabler Honest Health ($140 million), patient advocacy unicorn Solace ($130 million Series C), health system AI governance platform Qualified Health ($125 million), care navigation startup Garner Health ($118 million Series D at a $1.35 billion valuation), Alzheimer's device maker Cognito Therapeutics ($105 million), and women's midlife virtual care provider Midi Health ($100 million Series D, crossing unicorn status in the process).
Across all 110 deals in the quarter, the average deal size climbed to $36.7 million — the highest Rock Health has tracked since Q4 2021, up from $29.3 million a year ago.
AI Is No Longer a Category
Perhaps the most telling editorial decision in Rock Health's Q1 report was one they made about their own methodology. The firm announced it is retiring its practice of separately tracking "AI-enabled" startups — a category it has maintained for several years — because the distinction has become meaningless.
"AI is now the operating environment," the report states. Rock Health's analysts noted that pretty much every digital health startup is AI-enabled in one way or another, and that singling out the category no longer carries informational value. The broader venture market appears to agree: AI investment kept climbing globally in Q1 2026, and frontier lab valuations hit eye-watering new heights, even as open questions about the cost of running foundation models and AI's longer-term economic impact remain unresolved.
What this means for founders is a recalibration of what actually confers competitive advantage. "When everyone has AI, the technology stops being the differentiator," the Rock Health report noted. "The companies successfully raising are those moving earliest into complex, workflow-embedded use cases." OpenEvidence's integration into Epic EHR systems at Sutter Health and Mount Sinai is the clearest illustration of that logic playing out at scale.
Capital Concentrating, Deals Declining
The $4 billion headline masks a quieter story unfolding below the mega-deal waterline. Deal count fell to 110 in Q1 2026 from 122 in Q1 2025 — a 10% drop even as total dollars surged 33%. Fewer companies are getting funded. Those that are getting funded are getting dramatically more money. It is a bifurcation that Rock Health had flagged as a defining feature of the market coming into 2026, describing 2025 as "the year of haves and have-nots." Q1 suggests that dynamic is entrenching rather than correcting.
The exit window, meanwhile, remains narrow. WHOOP's IPO signaling is an outlier in a landscape where most high-profile digital health candidates — many of them waiting in the wings since Hinge Health and Omada Health set a high bar with their 2025 public debuts — are still biding their time. M&A activity saw 43 deals in Q1, a modest uptick from the prior quarter, with acquihires rather than transformative consolidation dominating the action.
Policy Tailwinds Begin to Materialize
Beyond the capital markets, Q1 brought early evidence that regulatory and reimbursement conditions are beginning to favor digital health at scale. CMMI's ACCESS Model payment rates went live in February, creating a framework that rewards measurable outcome improvements and is specifically designed to make technology-enabled care economically viable. Nearly every major payer in the country has pledged to adopt the model's outcome-aligned payment approach, extending its reach well beyond the 33 million Original Medicare beneficiaries it formally covers.
Extended telehealth flexibilities running through 2027, clearer FDA guidance on low-risk wellness products, and new federal pressure on interoperability and information blocking are adding further structural support to the sector. "The policy tailwinds we flagged last year are starting to take shape," Rock Health's analysts wrote — a measured assessment from a firm that has watched digital health cycle through multiple boom-and-bust phases since its founding.
What Comes Next
The pace of Q1 is not guaranteed to hold. Rock Health noted that macroeconomic conditions have remained volatile into April — geopolitical risk, oil price swings, uneven employment figures, and inflation anxiety are all present in the backdrop — and that the next few quarters will determine whether the momentum is durable or whether it is being inflated by a small number of AI-narrative-driven bets that have yet to prove out at scale.
At the current pace, 2026 would close with nearly 50 mega-deals in digital health — almost double 2025's count. Whether the companies lining up for those rounds can convert concentrated capital into durable clinical and commercial outcomes is the question that will define the sector's next chapter. For now, the money is moving — and it is moving fast, to fewer places, with higher expectations attached.
---
Sources: Rock Health Q1 2026 Funding Overview (April 6, 2026); Healthcare Dive; MedCity News; Fierce Healthcare; PitchBook Q1 2026 Healthtech VC Trends; PYMNTS.com.
"When everyone has AI, the technology stops being the differentiator."— Rock Health, Venture fund and digital health research firm